DENTSPLY SIRONA

Dentsply Sirona, Inc. engages in the design, manufacture, sales and distribution of professional dental products and technologies. It operates through the following segments: Technologies and Equipment and Consumables. The Technologies and Equipment segments comprises dental technology, equipment and healthcare consumable products such as dental implants, laboratory dental products, computer-aided design and computer-aided manufacturing systems, imaging systems, treatment centers and consumable medical device products. The Consumables segment offers preventive, restorative, instruments, endodontic and orthodontic dental products. The company was founded in 1899 and is headquartered in Charlotte, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Dentsply Sirona (XRAY) exceeds Q4 expectations, focuses on innovation

Dentsply Sirona (XRAY) reported strong financial performance in Q4 2022, with a strategic focus on digitalization and innovation. Despite challenges in organic sales and supply chain constraints, the company aims for margin improvement and growth opportunities through investments and pricing strategies. Restructuring efforts and acquisitions are set to drive profitability and market share gains.

Dentsply Sirona reports robust Q1 growth, eyes digital innovation

Dentsply Sirona's strong Q1 performance driven by Consumables and Aligners segments.
Challenges include mixed regional performance and cautious outlook on equipment demand.
Opportunities lie in digitalization, DSO partnerships, and growth in China and EPS targets.
Overall, a positive outlook with strategic focus on innovation and customer experience.

Dentsply Sirona exceeds Q2 expectations, eyes growth amid challenges

Dentsply Sirona reported strong financial performance in Q2 2023, exceeding expectations and raising full-year outlook across key financial metrics.
The company's strategic focus on growth, profitability, and digitalization, coupled with investments in key regions and product innovation, positions it for sustained success.
While facing challenges in certain markets and operational areas, Dentsply Sirona remains optimistic about opportunities for growth, innovation, and value creation in the dental industry.
Overall, Dentsply Sirona's performance highlights operational strengths, market positioning, and a forward-looking approach to driving shareholder value and market expansion.

DENTSPLY SIRONA reports mixed Q3 results, focuses on innovation and growth

DENTSPLY SIRONA's Q3 performance showed mixed results with challenges in certain markets but strength in key segments like CAD/CAM and Aligners.
The company is focused on driving value through innovation, maintaining a commitment to long-term plans, and navigating external challenges with confidence.
Despite headwinds, DENTSPLY SIRONA remains within guidance range for the year, with a strategic focus on volume growth and market expansion opportunities.

DENTSPLY SIRONA anticipates double-digit EPS growth in 2024

DENTSPLY SIRONA's Q4 2023 performance showed growth in key segments, with strategic initiatives set for 2024 as an inflection year for double-digit EPS growth.
The company is focusing on innovation, SKU optimization, and operational efficiency to drive profitability and revenue growth.
Challenges lie in certain segments and the need for organic growth normalization by 2025, but opportunities exist in new product launches and margin expansion.
Overall, DENTSPLY SIRONA is poised for accelerated profitable growth, with 2024 expected to be a pivotal year for improved performance.

DENTSPLY SIRONA reports mixed Q1 performance amidst innovation focus

DENTSPLY SIRONA navigated challenges in Q1 with a focus on innovation, sustainability, and strategic updates. While facing headwinds in certain segments and markets, the company aims to capitalize on growth opportunities through product launches and strategic initiatives.

DENTSPLY Sirona navigates revenue decline with strategic restructuring plans

DENTSPLY Sirona's Q2 performance reflects revenue decline and margin contraction, prompting strategic restructuring and focus on customer-centric initiatives. While facing challenges from macroeconomic factors and restructuring impacts, the company aims to leverage opportunities in shareholder returns and market dynamics to drive growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dentsply Sirona, Inc. engages in the design, manufacture, sales and distribution of professional dental products and technologies. It operates through the following segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment is engaged in designing, manufacturing, and selling dental technology and equipment products. The Essential Dental Solutions segment designs, manufactures, and sells value-added endodontic, restorative, and preventive consumable products. The Orthodontic and Implant Solutions segment designs, manufactures, and sells various digital implant systems and dental implant products. The Wellspect Healthcare segment designs, manufactures, and sells continence care solutions for management of both urinary and bowel dysfunction dental products. The company was founded in 1899 and is headquartered in Charlotte, NC.

NEW YORK , May 13, 2022 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of DENTSPLY SIRONA Inc. (NASDAQ: XRAY) resulting from allegations that Dentsply Sirona may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Dentsply Sirona securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED LAW FIRM, Encourages DENTSPLY SIRONA Inc. Investors with Losses to Inquire About Securities Class Action Investigation - XRAY

Boston, Massachusetts--(Newsfile Corp. - May 13, 2022) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Dentsply Sirona Inc. ("Dentsply" or the "Company") (NASDAQ: XRAY), a manufacturer of professional dental products and technologies. On April 19, 2022, the Company filed a Form 8-K announcing that Donald M. Casey Jr. had been "terminated as the Company's Chief Executive Officer and has ceased to serve as a member of the...

Berman Tabacco Announces Investigation of DENTSPLY SIRONA Inc. (XRAY) for Potential Securities Law Violations

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Dentsply Sirona Inc. (“Dentsply” or the “Company”) (NASDAQ: XRAY). The investigation concerns whether Dentsply has violated the federal securities laws and/or engaged in other unlawful business practices. Dentsply is a dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries. On April 19, 2022, Dentsply stated that the Company's Chief Exec

Kirby McInerney LLP Announces an Investigation of Shareholder Claims on Behalf of Dentsply Sirona Inc. (XRAY) Investors

SAN FRANCISCO , May 12, 2022 /PRNewswire/ -- Hagens Berman urges DENTSPLY SIRONA, Inc. (NASDAQ: XRAY) investors with significant losses to submit your losses now.  Visit: www.hbsslaw.com/investor-fraud/XRAY Contact An Attorney Now: XRAY@hbsslaw.com                                               844-916-0895 DENTSPLY SIRONA, Inc. (XRAY) Investigation: The investigation focuses on DENTSPLY's assurances that its financial statements fairly presented in all material respects the financial condition of the company.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages DENTSPLY SIRONA Inc. (XRAY) Investors with Significant Losses to Contact Firm's Attorneys, XRAY's Former CFO "Departs" Moderna Days After DENTSPLY Announces Probe of Financial Reporting

Los Angeles, California--(Newsfile Corp. - May 12, 2022) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DENTSPLY SIRONA Inc. ("Dentsply" or "the Company") (NASDAQ: XRAY) for violations of the securities laws.The investigatio

Investigation Alert: The Schall Law Firm Encourages Investors in DENTSPLY SIRONA Inc. with Losses of $100,000 to Contact the Firm

RADNOR, Pa.--(BUSINESS WIRE)--Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of DENTSPLY SIRONA Inc. (NASDAQ: XRAY) Investors

Investigation Alert:  Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of DENTSPLY SIRONA Inc. (NASDAQ: XRAY) Investors

BENSALEM, Pa. , May 11, 2022 /PRNewswire/ -- Law Offices of Howard G.

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of Dentsply Sirona Inc. (XRAY) on Behalf of Investors

LOS ANGELES , May 11, 2022 /PRNewswire/ -- The Law Offices of Frank R. Cruz continues its investigation of Dentsply Sirona Inc. ("Dentsply" or the "Company") (NASDAQ: XRAY) on behalf of investors concerning the Company's possible violations of federal securities laws.

The Law Offices of Frank R. Cruz Continues Its Investigation of Dentsply Sirona Inc. (XRAY) on Behalf of Investors

LOS ANGELES , May 11, 2022 /PRNewswire/ --  Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, continues its investigation on behalf of Dentsply Sirona Inc. ("Dentsply" or the "Company") (NASDAQ: XRAY) investors concerning the Company's possible violations of the federal securities laws.   If you suffered a loss on your Dentsply investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/dentsply-sirona-inc-1/.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Dentsply Sirona Inc. (XRAY) on Behalf of Investors

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of DENTSPLY SIRONA Inc. (NASDAQ: XRAY) resulting from allegations that Dentsply Sirona may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Dentsply Sirona securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency

EQUITY ALERT: Rosen Law Firm Encourages DENTSPLY SIRONA Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – XRAY

Dentsply Sirona Inc's (NASDAQ: XRAY) Q1 FY22 sales decreased 6.1% Y/Y to $965 million, missing the consensus of $988.43 billion. Adjusted EPS decreased to $0.52 from $0.72 a year ago and missed the consensus of $0.56.

Dentsply Sirona's Q1 Earnings Miss Street Expectations, Cuts FY22 Guidance

DENTSPLY SIRONA Inc. (NASDAQ:XRAY ) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Andrea Daley - VP, IR John Groetelaars - Interim CEO Barbara Bodem - CFO Conference Call Participants Elizabeth Anderson - Evercore Kevin Caliendo - UBS Jason Bednar - Piper Sandler Erin Wright - Morgan Stanley Jeff Johnson - Baird Jon Block - Stifel Matt Miksic - Credit Suisse Rachel Vatnsdal - JPMorgan Operator Welcome to the Dentsply Sirona First Quarter 2022 Results Conference Call. All participants will be listen-only mode.

DENTSPLY SIRONA Inc. (XRAY) Q1 2022 Results - Earnings Call Transcript

DENTSPLY SIRONA's (XRAY) preliminary first-quarter 2022 results reflect weakness in segments.

DENTSPLY SIRONA (XRAY) Reports Weak Q1 Preliminary Results

CHARLOTTE, N.C., May 10, 2022 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced its preliminary financial results for the first quarter of 2022.

Dentsply Sirona Reports Preliminary First Quarter 2022 Results

Los Angeles, California--(Newsfile Corp. - May 6, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DENTSPLY SIRONA Inc. ("Dentsply" or "the Company") (NASDAQ: XRAY) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Dentsply announced on April 19, 2022, that its CEO had been...

Ongoing Investigation Notice: The Schall Law Firm Encourages Investors in DENTSPLY SIRONA Inc. with Losses of $100,000 to Contact the Firm

We think that DENTSPLY stock (NASDAQ: XRAY), a dental equipment company, is currently a better pick than Teva Pharmaceuticals stock (NYSE: TEVA), despite it being the more expensive of the two, trading at 2.0x trailing revenues compared to 0.5x for Teva.

DENTSPLY Stock Is Likely To Offer Superior Returns Over This Pharmaceuticals Company

Los Angeles, California--(Newsfile Corp. - May 5, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DENTSPLY SIRONA Inc. ("Dentsply" or "the Company") (NASDAQ: XRAY) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Dentsply announced on April 19, 2022, that its CEO had been...

Ongoing Investigation Reminder: The Schall Law Firm Encourages Investors in DENTSPLY SIRONA Inc. with Losses of $100,000 to Contact the Firm

Today's virtual global event sets the stage for the launch of DS Core – a cloud-based solution powered by the collaboration between Dentsply Sirona and Google Cloud. Dentsply Sirona also introduces two new service offerings: DS Core Create and DS Core Care.

Dentsply Sirona opens the gateway to a new digital universe with cloud-based solution DS Core

Los Angeles, California--(Newsfile Corp. - May 4, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DENTSPLY SIRONA Inc. ("Dentsply" or "the Company") (NASDAQ: XRAY) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Dentsply announced on April 19, 2022, that its CEO had been...

Investigation Notice: The Schall Law Firm Encourages Investors in DENTSPLY SIRONA Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm Encourages Investors in DENTSPLY SIRONA Inc. with Losses of $100,000 to Contact the Firm

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in DENTSPLY SIRONA Inc. with Losses of $100,000 to Contact the Firm

Dentsply Sirona is overly punished by the market, due to undisclosed reasons for termination of its previous CEO, Don Casey, and its lowered outlook for its Q1 2022. Although unfavorable news rumors have cooled down, the market appears set to consolidate at the present trading range.

Dentsply Sirona Seems Unaffected By Management Reshuffles

DENTSPLY SIRONA's (XRAY) first-quarter results are likely to reflect strong performance at Technologies & Equipment business.

DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--WellAir, a leading indoor air disinfection and purification solutions provider, today announced that Kari Dixon has been appointed as the company's President and Chief Executive Officer. As a capital markets veteran, Dixon has served as WellAir's Chief Financial Officer since she joined the company in 2021. Todd M. Pope has been named Vice-Chair of the Board of Directors. "It has been an honor to serve as the President and CEO of WellAir during the

WellAir Announces Kari Dixon as President and Chief Executive Officer

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Dentsply Sirona, Inc. (“Dentsply” or the “Company”) (NASDAQ: XRAY) on behalf of Dentsply stockholders. Our investigation concerns whether Dentsply has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On April 19, 2022, the Company issued a press release announci

DENTSPLY ALERT: Bragar Eagel & Squire, P.C. is Investigating Dentsply Sirona, Inc. on Behalf of Dentsply Stockholders and Encourages Investors to Contact the Firm

HC Wainwright has cut the price target for Dentsply Sirona Inc (NASDAQ: XRAY) from $58 to $48 (17% upside), reiterating the Neutral rating. The analysts have adjusted 2022 projections to reflect lower than expected Q1 FY22 earnings.

News for DENTSPLY SIRONA Stock (XRAY)